Pharming二季度收入低于预期并下调2026年收入指引

U.S. launches fresh strikes on Iran as fighting intensifies across Middle East
Introduction & Market Context
Pharming Group N.V. (NASDAQ:PHAR, EURONEXT:PHARM) presented its second quarter and first half 2026 financial results on July 30, 2026, revealing a company in transition as newer product Joenja gains momentum while legacy therapy RUCONEST faces competitive headwinds. The presentation highlighted a 40% year-over-year revenue increase for Joenja, but this growth couldn’t fully offset a 10% decline in RUCONEST sales, resulting in total Q2 revenue of $90.2 million—a miss against analyst expectations that sent shares down 22% to $0.855, near the stock’s 52-week low of $0.834.
The company lowered its full-year 2026 revenue guidance by $30 million to a range of $375-395 million while simultaneously improving operating expense guidance by $15 million to $315-320 million, signaling both revenue challenges and cost discipline as it invests more than $40 million in research and development to advance its pipeline.
Quarterly Performance Highlights
As shown in the following revenue comparison chart, Pharming’s Q2 2026 total revenue of $90.2 million represented a 3% year-over-year decline, with divergent trends between its two commercial products.
RUCONEST, the company’s hereditary angioedema (HAE) treatment, generated $72.3 million in Q2 2026, down 10% from $80.4 million in the prior-year quarter but up 24% sequentially from Q1 2026. Management attributed the year-over-year decline to competition from a new oral on-demand HAE treatment launched in 2025, though sequential improvement suggests stabilization may be underway.
Joenja (leniolisib), approved for APDS (Activated PI3K Delta Syndrome), delivered $17.9 million in revenue, up 40% from $12.8 million in Q2 2025. This growth was driven by both U.S. market penetration and accelerating international expansion, with EU and rest-of-world revenue surging 150% year-over-year to $2.5 million.
The following financial highlights chart illustrates the company’s overall Q2 performance across key metrics:
Adjusted operating profit declined to $7.9 million from $12.9 million in Q2 2025, impacted by one-time manufacturing inventory impairments and lower revenue. Operating cash flow turned negative at $(9.7) million compared to positive $11.7 million in the prior-year quarter, primarily due to working capital movements. Cash and marketable securities stood at $159.5 million at quarter-end, down $12.3 million from Q1 2026.
For the first half of 2026, total revenue reached $162.7 million, down 6% from $172.3 million in H1 2025, as illustrated in the following half-year comparison:
RUCONEST Resilience Amid Competition
Despite facing its first significant on-demand oral competitor in the HAE market, RUCONEST demonstrated what management characterized as "resilience" in maintaining its patient base and showing signs of renewed momentum.
The following performance breakdown details RUCONEST’s Q2 metrics across financial performance, demand indicators, and patient retention:
Key resilience indicators included an active patient base at 93% of year-ago levels one year after the oral competitor launch, 84 new patient enrollments in Q2 2026, and the addition of 17 new prescribers. Management emphasized that RUCONEST revenue is expected to stabilize with a return to growth during the second half of 2026.
The company’s presentation highlighted RUCONEST’s differentiated value proposition in treating high-burden HAE patients, as shown in this market positioning overview:
RUCONEST targets the root cause of HAE across all pathways and is primarily used by patients experiencing more severe or frequent attacks. The presentation noted that the "overwhelming majority of RUCONEST patients remain on therapy one year into oral competitor launch," suggesting the product maintains a defensible position among its core patient population.
Clinical efficacy data presented showed strong attack resolution metrics:
According to the presentation, 97% of acute attacks required just one dose of RUCONEST, with the treatment stopping 93% of attacks for at least three days and achieving a median time to complete attack resolution of 4.5 hours.
Joenja Growth Momentum and Expansion
Joenja emerged as Pharming’s primary growth driver, with the following detailed update showing strong momentum across both U.S. and international markets:
The number of U.S. patients on Joenja therapy reached 132 in Q2 2026, up 16% from 114 patients in Q2 2025, representing steady quarter-over-quarter growth. The company identified an additional 16 U.S. patients during the quarter, expanding the addressable patient pool.
International expansion accelerated significantly, with Germany launching in July 2026 and Japan expected to launch in Q3 2026. U.S. revenue grew 31% year-over-year to $15.4 million, while international revenue jumped 150% to $2.5 million, albeit from a smaller base.
The company’s strategic expansion plan for Joenja illustrates a pathway from the established APDS commercial base toward blockbuster potential:
Key expansion drivers include a pediatric supplemental New Drug Application (sNDA) accepted by the FDA with a PDUFA date of October 24, 2026, focused geographic expansion that doubles the addressable opportunity, and exploration of broader primary immunodeficiencies (PIDs) and common variable immunodeficiency (CVID) markets representing more than 15,000 potential U.S. patients.
Pipeline Progress and Blockbuster Potential
Pharming’s presentation emphasized its "high-value pipeline" with two programs each targeting more than $1 billion in revenue potential, positioning the company as what CEO Fabrice Chouraqui described as "a more diversified rare disease company."
The following overview illustrates the company’s three-pillar strategy across HAE, PIDs, and primary mitochondrial disease:
The scientific rationale for expanding leniolisib beyond APDS centers on PI3Kδ as a master regulator of immune function. The following diagram explains this mechanism:
Validation of PI3Kδ inhibition in APDS provides a foundation for broader application:
The presentation highlighted sustained, durable efficacy with lymph node and spleen volume reductions maintained through multi-year open-label extension studies, established safety and tolerability with primarily mild-to-moderate adverse events and no treatment-related serious adverse events over up to seven years of therapy, and clinically meaningful improvements including reduced infections, fewer hospitalizations, and lower treatment burden.
The expansion opportunity targets shared PI3Kδ-driven immune dysregulation across multiple conditions:
Two fully enrolled Phase II trials are evaluating leniolisib in broader patient populations, with topline results expected in Q4 2026:
The CVID trial is an open-label, single-arm, multi-center study with 20 patients, while the genetic PIDs trial is an open-label, single-arm basket trial at the NIH enrolling 12 patients across multiple genetic conditions (ALPS-FAS, CTLA4, NFKB1, PTEN, SOCS1, NRAS/KRAS RALD). Both trials are evaluating dose-ranging from 10 mg to 70 mg twice daily with a shared three-year open-label extension.
Primary endpoints include lymph node and spleen size, blood cell counts, lung and liver end-organ measures, novel and indication-specific patient and clinician outcomes, and biomarkers including CXCL13 and B cells. Management aims to demonstrate clinically meaningful reductions in lymphoproliferation and cytopenias, end-organ stabilization, and supportive biomarker shifts to establish proof of concept and confirm optimal dosing.
Financial Analysis and Guidance
The company’s revised 2026 financial guidance reflects the revenue challenges from RUCONEST while maintaining investment in growth initiatives:
Full-year 2026 revenue guidance of $375-395 million implies 0-5% growth in constant currency, down $30 million from prior guidance. Operating expense guidance of $315-320 million represents 1-3% growth and includes more than $40 million in incremental R&D spending to advance the pipeline, offset by $9 million in G&A structural cost reductions announced in October 2025.
Management emphasized that available cash and future cash flows are expected to cover current pipeline and pre-launch costs, maintaining financial flexibility without requiring additional capital raises in the near term.
The presentation concluded with an updated outlook summary:
Forward-Looking Statements
Looking ahead, Pharming outlined several near-term milestones expected to drive value creation. For RUCONEST, revenues are expected to stabilize with a return to growth during the second half of 2026. For Joenja in APDS, the company anticipates geographic expansion and pediatric label expansion in the U.S. The broader leniolisib program targets two Phase II trial readouts for the CVID patient population in Q4 2026.
Management also highlighted the FALCON pivotal study with napazimone (KL1333) in mtDNA mitochondrial disease, which completed a positive futility analysis and is expected to report final results in 2027.
The company characterized its strategic focus as building "a leading rare disease company" through a more disciplined operating model, scalable organization, and value creation focus. However, the significant revenue miss and guidance reduction underscore execution challenges in the transition from RUCONEST dependence to a more diversified portfolio, with the market’s 22% single-day stock decline reflecting investor skepticism about the pace of this transformation.
Success in the upcoming Phase II readouts for leniolisib in broader immunodeficiency indications could validate the blockbuster potential management projects, potentially expanding Joenja’s addressable market to more than $1 billion in annual sales. Conversely, disappointing results could leave the company more dependent on stabilizing RUCONEST and incremental APDS growth, limiting near-term upside potential.
Full presentation:
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.